Learn more about Hexima’s technology.
Hexima is conducting a phase I/IIa clinical trial of its lead antifungal molecule, HXP124, as a treatment for fungal nail infections.
Hexima Limited has released its Interim Financial Report for the six months ended 31 December 2019. View Interim Financial Report (pdf)
Presentations and Results from the 2019 Hexima Limited Annual General Meeting held 19 November 2019. AGM 2019 Chairman’s Address AGM 2019 CEO Presentation AGM 2019 Meeting Results
Please be advised that the Hexima Limited 2019 Annual General Meeting (AGM) will be held at 3:30pm on Tuesday, 19 November 2019 at MinterEllison, Level 23, Rialto Towers, 525 Collins Street, Melbourne, Victoria. Registration will commence at 3:00pm. A letter from the...
Hexima has today released their Annual Financial Report for the year ended June 30 2019 View update from CEO and Chairman (pdf) View Annual Financial Report for the year ended June 30 2019 (pdf)
Hexima Limited is pleased to announce the appointment of Mr Michael Aldridge as Chief Business Officer and a member of the Board of Directors, effective 21 May 2019. Mr Aldridge will be based in San Francisco, focussing on business development and establishing...